NEW YORK – One of the hottest categories in the diagnostics space is antimicrobial-resistance testing – and a subset of AMR testing, antibiotic-resistance testing – where there is no shortage of companies looking to cash in on what some say is a multiplying crisis fueled by the overuse of antibiotics.
In spite of that, companies offering new technologies in the space, or trying to break into it, have in, large part, struggled in recent years, and investors have been left scratching their heads wondering when their investments will bear fruit.